Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis

Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements

It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.

All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.

Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.

All patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.

The result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.

Studieöversikt

Detaljerad beskrivning

The aim of the study:: To develop and evaluate the diagnostic efficacy of a screening method for significant coronary artery stenosis based on data obtained from the analysis of a single-channel electrocardiogram.

This is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first group comprises 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second group is a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.

All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion. Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as clinically indicated. ECG registration in standard lead I will be performed within 3 months before or after the CAG or MSCT.

Obtained data will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.

The single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124.

The result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.

The patient's personal data (last name, first name, patronymic, date of birth, contact information) will not be transferred or taken into account. Each patient is assigned an individual number that is not associated with his/her personal data.

Subsequently, spectral analysis of the electrocardiogram will be performed using machine learning models and/or neural network data analysis.

Then a spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform, the principles of which are based on the Fourier transform.

Analysis of the single-channel ECG involves evaluation of the following parameters (the parameters listed below will be calculated as median beat-to-beat values):

  • TpTe - time from peak to end of the T-wave
  • VAT - time from the beginning of the QRS to the R-peak
  • QTc - corrected QT interval.
  • QT/TQ - the ratio of QT length to TQ length (from the end of T to the beginning of the QRS of the next complex).
  • QRS_E - total energy of the QRS-wave based on wavelet transform
  • T_E - total energy of the T-wave based on wavelet transform
  • TP_E - energy of the main T-wave peak based on wavelet transform
  • BETA, BETA_S - T-wave asymmetry coefficients (simple and smoothed versions)
  • BAD_T - flag of T-wave quality (whether expressed in the current lead)
  • QRS_D1_ons - energy of the leading edge of the R-wave (based on the "first derivative" wavelet transform)
  • QRS_D1_offs - energy of the trailing edge of the R-wave (based on the "first derivative" wavelet transform)
  • QRS_D2 - peak energy of the R-wave (based on the "second derivative" wavelet transform)
  • QRS_Ei (i=1,2,3,4) - QRS-wave energy in 4 frequency ranges (2-4-8-16-32 Hz) based on wavelet transform
  • T_Ei (i=1,2,3,4) - T-wave energy in 4 frequency ranges (2-4-6-8-10 Hz) based on wavelet transform
  • HFQRS - amplitude of the high-frequency components of the QRS-wave

Additionally used parameters:

  • TpTe, VAT, QTc - are duplicated to control the correctness of record processing (the value of the central measure should be approximately equal to the beat-to-beat median).
  • QRSw - QRS width.
  • RA, SA, TA - amplitudes of the R, S, T-waves, respectively, used for normalizing the parameters listed above.

Method of statistical processing of results: SPSS Statistics Version 26 computer program for statistical data processing; construction of machine learning models and/or neural network data analysis The proposed research outcome: development of an algorithm for diagnosing significant coronary stenosis based on single-channel ECG data using elements of artificial intelligence.

The endpoints of the study are the parameters of diagnostic accuracy of the developed model:

  • specificity,
  • sensitivity,
  • prognostic significance of a positive and negative result,
  • diagnostic accuracy.

Тhese metrics will be calculated using receiver operating characteristic (ROC) analysis and confusion matrices on a held-out test set (30% of the dataset) after training multifactorial models (logistic regression, random forest, or neural networks) on single-lead ECG features. Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of significant coronary stenosis (≥50% lumen narrowing per CAG/MSCT) against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.

Studietyp

Observationell

Inskrivning (Beräknad)

400

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Moscow, Ryssland, 119435
        • 1 University Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion. Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as clinically indicated. ECG registration in standard lead I will be performed within 3 months before or after the CAG or MSCT.

Beskrivning

Inclusion Criteria:

  • Presence of written informed consent from the patient to participate in the study.
  • Age 18 years and older.
  • Outpatient visit and/or hospitalization at the research center with coronary visualization performed.

Non-inclusion criteria:

  • Absence of sufficient data on coronary anatomy and stenosis significance.
  • Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).
  • Absence of written informed consent from the patient to participate in the study.

Exclusion Criteria:

  • Patient's unwillingness to continue participation in the study.
  • Inability to perform full analysis of single-channel ECG digital characteristics.
  • Refusal of coronary visualization methods for any reason.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
coronary artery stenosis
200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results
The single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124
control group
200 patients without significant stenosis according to CAG or MSCT data
The single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sensitivity, specificity, positive/negative predictive values, and overall accuracy
Tidsram: From July 2027 to August 2027
Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of significant coronary stenosis (≥50% lumen narrowing per CAG/MSCT) against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
From July 2027 to August 2027

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

  • Analysis of transitions between linear and nonlinear cardiac rhythm modes in patients with ischemic heart disease / L. V. Mezentseva, P. Sh. Chomakhidze, F. Yu. Kopylov [et al.] // Pathogenesis. - 2017. - Vol. 15, No. 1. - P. 54-58. - DOI 10.25557/GM.2017.1.6952. - EDN ZFALML.
  • Simakov, Sergey, Gamilov, Timur, Danilov, Alexander, Kopylov, Philipp, Chomakhidze, Peter and Liang, Fuyou. "Hemodynamics in residual myocardial ischemia". BIOKYBERNETIKA: Mathematics for Theory and Control in the Human and in Society, edited by Jochen Mau, Sergey Mukhin, Guanyu Wang and Shuhua Xu, Berlin, Boston: De Gruyter, 2025, pp. 319-334. https://doi.org/10.1515/9783111341996-017

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 maj 2026

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

9 februari 2026

Först inskickad som uppfyllde QC-kriterierna

6 maj 2026

Första postat (Faktisk)

12 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 maj 2026

Senast verifierad

1 april 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

It is not possible to provide documentation due to the prohibition received from the local ethics committee

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera